FAHD2A

Across TCGA pan-cancer cohorts, FAHD2A RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of FAHD2A’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where FAHD2A RNA is repressed in tumor relative to normal tissue. In most cancer types FAHD2A is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and LIHC are the cancer types where FAHD2A tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FAHD2A RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	IV	−1.757	<.001	11	view →
KIRC	Male	II,III,IV	−0.554	<.001	9	view →
LIHC	Male	II,III,IV	−0.681	<.001	8	view →
BRCA	All	All	−0.682	<.001	6	view →
READ	All	All	+0.412	.001	6	view →
LUSC	Male	All	+0.414	<.001	5	view →
KIRP	All	IV	+0.282	.009	5	view →
KICH	Female	II,III,IV	−1.017	<.001	4	view →
COAD	Male	II,III,IV	+0.348	<.001	4	view →
CHOL	All	All	−0.658	<.001	3	view →
STAD	All	II,III,IV	+0.395	.005	3	view →
BLCA	All	All	+0.339	.008	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

FAHD2A–THCA

Open the THCA breakdown →